alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[ARTICLE] 6
[CIK] 0000880583
[NAME] JURIKA & VOYLES CORE EQUITY PORTFOLIO
[SERIES]
   [NUMBER] 21
   [NAME] THE TRAVELERS SERIES TRUST
<TABLE>
<S>                             <C>
[PERIOD-TYPE]                   YEAR
[FISCAL-YEAR-END]                          DEC-31-1999
[PERIOD-END]                               DEC-31-1999
[INVESTMENTS-AT-COST]                        8,512,466
[INVESTMENTS-AT-VALUE]                       9,098,172
[RECEIVABLES]                                  337,691
[ASSETS-OTHER]                                     318
[OTHER-ITEMS-ASSETS]                                 0
[TOTAL-ASSETS]                               9,436,181
[PAYABLE-FOR-SECURITIES]                       201,825
[SENIOR-LONG-TERM-DEBT]                              0
[OTHER-ITEMS-LIABILITIES]                       28,326
[TOTAL-LIABILITIES]                            230,151
[SENIOR-EQUITY]                                      0
[PAID-IN-CAPITAL-COMMON]                     8,211,764
[SHARES-COMMON-STOCK]                          812,776
[SHARES-COMMON-PRIOR]                          600,523
[ACCUMULATED-NII-CURRENT]                       46,031
[OVERDISTRIBUTION-NII]                               0
[ACCUMULATED-NET-GAINS]                        362,529
[OVERDISTRIBUTION-GAINS]                             0
[ACCUM-APPREC-OR-DEPREC]                       585,706
[NET-ASSETS]                                 9,206,030
[DIVIDEND-INCOME]                               88,027
[INTEREST-INCOME]                               32,982
[OTHER-INCOME]                                       0
[EXPENSES-NET]                                  74,795
[NET-INVESTMENT-INCOME]                         46,214
[REALIZED-GAINS-CURRENT]                       430,659
[APPREC-INCREASE-CURRENT]                      317,311
[NET-CHANGE-FROM-OPS]                          794,184
[EQUALIZATION]                                       0
[DISTRIBUTIONS-OF-INCOME]                            0
[DISTRIBUTIONS-OF-GAINS]                             0
[DISTRIBUTIONS-OTHER]                                0
[NUMBER-OF-SHARES-SOLD]                        599,062
[NUMBER-OF-SHARES-REDEEMED]                        776
[SHARES-REINVESTED]                              2,237
[NET-CHANGE-IN-ASSETS]                       3,037,027
[ACCUMULATED-NII-PRIOR]                            420
[ACCUMULATED-GAINS-PRIOR]                     (68,733)
[OVERDISTRIB-NII-PRIOR]                              0
[OVERDIST-NET-GAINS-PRIOR]                           0
[GROSS-ADVISORY-FEES]                           60,520
[INTEREST-EXPENSE]                                   0
[GROSS-EXPENSE]                                104,721
[AVERAGE-NET-ASSETS]                         7,480,140
[PER-SHARE-NAV-BEGIN]                            10.27
[PER-SHARE-NII]                                   0.06
[PER-SHARE-GAIN-APPREC]                           1.00
[PER-SHARE-DIVIDEND]                              0.00
[PER-SHARE-DISTRIBUTIONS]                         0.00
[RETURNS-OF-CAPITAL]                                 0
[PER-SHARE-NAV-END]                              11.33
[EXPENSE-RATIO]                                   1.00
</TABLE>
IN RE Robbie Gene WATSON, Jr., Petitioner.

No. 19-8282.

Supreme Court of the United States.

May 18, 2020

Petition for writ of habeas corpus denied.
Amendment to Employment Agreement dated May 8, 2012 with Stephen Aselage



 Exhibit 10.3 
 AMENDMENT NO. 1 TO 
 EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment”) made as of May 8, 2012 (“Effective
Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Stephen Aselage (“Employee”). 
  

	1.	This Amendment No. 1 is intended to amend and modify that certain Amended and Restated Employment Agreement by and between the Company and Employee dated
January 1, 2009 (the “Agreement”). The Agreement, together with this Amendment, shall constitute a single agreement. Capitalized terms not otherwise defined in this Amendment shall have the meaning ascribed to such terms in the
Agreement. Except as expressly modified by this Amendment, the Agreement shall remaining full force and effect according to its terms. 

  

	2.	The defined term “Termination Compensation,” as provided in Section 7(c) of the Agreement, is hereby deleted and replaced in its entirety by the
following definition: 

 Termination Compensation. For purposes of this Agreement, the term
“Termination Compensation” shall mean: (i) one hundred fifty percent (150%) of the Employee’s then current annual base salary which shall be payable in a lump sum within two weeks after separation of employment, conditioned
on Employee executing the Company’s standard form severance and release agreement, and shall be subject to customary withholding and other applicable payroll processes. Employee shall execute the Company’s standard form severance and
release agreement within sixty (60) days after the Employee’s termination. 
  

	3.	This Amendment No. 1 may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and
the same instrument. 

 IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment as of the
date first written above. 
  

							
	BIOMARIN PHARMACEUTICAL INC.	 	EMPLOYEE
				
	By:	 	 /s/ Jean-Jacques Bienaimé
	 	By:	 	 /s/ Stephen Aselage

	Name:	 	Jean-Jacques Bienaimé	 		 	Stephen Aselage
	Its:	 	Chief Executive Officer
EXHIBIT 23.1









CONSENT OF INDEPENDENT PETROLEUM ENGINEERS



We hereby consent to the references to our firm in the form and
context in which they are included in this Annual Report on Form 10-K (including any amendments thereto) filed by PermRock Royalty
Trust (“Annual Report”), to our estimates of reserves and value of reserves and our report on reserves as of December 31,
2019, December 31, 2020 and December 31, 2021 of the underlying properties and net profits interest owned by PermRock Royalty Trust
and to the inclusion of our report dated March 10, 2022 as an Exhibit to the Annual Report.









| | Sincerely,                             
| | ---------------------------------------
| |                                        
| |                                        
| |                                        
| | Cawley, Gillespie & Associates, Inc.   
| | Texas Registered Engineering Firm F-693



March 31, 2022

Fort Worth, Texas
IN RE Karl David KRETSER, Jr., Petitioner.

No. 19-6173

Supreme Court of the United States.

November 4, 2019

Petition for writ of habeas corpus denied.

Justice Kagan took no part in the consideration or decision of this petition.
<PAGE>

                                  Exhibit 11.1

             Statement Regarding Computation of Per Share Earnings
                   (In thousands, except per share amounts )


                                                      Quarter Ended 
                                                         March 31,  
                                                    ------------------
                                                     1997       1996
                                                    -------    -------
                                                                    
Net income                                          $39,671    $27,352
                                                                    
                                                                    
Weighted average number of common stock                             
and common stock equivalents outstanding during             
each period - primary                                42,235     45,653
                                                                    
Weighted average number of common stock                             
and common stock equivalents outstanding during             
each period - fully diluted                          42,132     45,782
                                                                    
                                                                    
                                                                    
Net earnings per  share - primary                   $  0.94    $  0.60
                                                    -------    -------
                                                    -------    -------
Net earnings per share - fully diluted              $  0.94    $  0.60
                                                    -------    -------
                                                    -------    -------
# C_2018365EN.01000102.xml

| 9.10.2018 | EN | Official Journal of the European Union | C 365/1 |
| --- | --- | --- | --- |

9.10.2018

EN

Official Journal of the European Union

C 365/1

---

Non-opposition to a notified concentration

(Case M.9114 — KKR/TPG Asia/KMK/Square Peg/PropertyGuru)

(Text with EEA relevance)

(2018/C 365/02)

On 28 September 2018, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32018M9114. EUR-Lex is the online access to European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32018M9114. EUR-Lex is the online access to European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

---
**Exhibit 32.1**

 

**WRITTENSTATEMENT**

**OF**

**CHIEFEXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER**

 

The undersigned herebycertify that the Form 10-Q for the quarter ended June 30, 2009 filedby TNS, Inc. with the Securities and Exchange Commission fully complieswith the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934 and that information contained in the reportfairly presents, in all material respects, the financial condition and resultsof operations of the issuer.

 
| Dated: August 10,  2009                                     |   |
|------------------------------------------------------------------|--------|
|                                                             |   |
| /s/ HENRY H. GRAHAM,  JR.                                        |   |
|                                                             |   |
| Henry H.  Graham, Jr.                                       |   |
| Chief Executive Officer                                          |   |
|                                                             |   |
| Dated: August 10,  2009                                     |   |
|                                                             |   |
| /s/ DENNIS L. RANDOLPH,  JR.                                     |   |
|                                                             |   |
| Dennis L.  Randolph, Jr.                                    |   |
| Executive Vice  President, Chief Financial Officer and Treasurer |   |

 

----
I 

113TH CONGRESS 

1ST SESSION H. R. 1125 

To amend the Internal Revenue Code of 1986 to provide for an exclusion 

for assistance provided to participants in certain veterinary student loan 

repayment or forgiveness programs. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 13, 2013 

Mr. SCHRADER introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL 

To amend the Internal Revenue Code of 1986 to provide 

for an exclusion for assistance provided to participants 

in certain veterinary student loan repayment or forgiveness programs. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Veterinary Medicine 

5 Loan Repayment Program Enhancement Act’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

2 

•HR 1125 IH

1 SEC. 2. EXCLUSION FOR ASSISTANCE PROVIDED TO PAR2 TICIPANTS IN CERTAIN VETERINARY STU3 DENT LOAN REPAYMENT OR FORGIVENESS 

4 PROGRAMS. 

5 (a) IN GENERAL.—Paragraph (4) of section 108(f) 

6 of the Internal Revenue Code of 1986 is amended— 

7 (1) by striking ‘‘or’’ after ‘‘such Act,’’, 

8 (2) by striking the period at the end and insert9 ing ‘‘, under section 1415A of the National Agricul10 tural Research, Extension, and Teaching Policy Act 

11 of 1977 (7 U.S.C. 3151a), or under any other State 

12 loan repayment or loan forgiveness program that is 

13 intended to provide for increased access to veteri14 nary services in such State.’’, and 

15 (3) by striking ‘‘STATE’’ in the heading and in16 serting ‘‘OTHER’’. 

17 (b) EFFECTIVE DATE.—The amendments made by 

18 this section shall apply to amounts received by an indi19 vidual in taxable years beginning after December 31, 

20 2012. 

Æ 

mstockstill on DSK4VPTVN1PROD with BILLS
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                         122,340
<INT-BEARING-DEPOSITS>                          12,527
<FED-FUNDS-SOLD>                             1,812,300
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                  2,238,537
<INVESTMENTS-CARRYING>                           2,057
<INVESTMENTS-MARKET>                             2,068
<LOANS>                                     10,869,302
<ALLOWANCE>                                  (113,000)
<TOTAL-ASSETS>                              15,485,216
<DEPOSITS>                                  11,669,092
<SHORT-TERM>                                   821,801
<LIABILITIES-OTHER>                            391,050
<LONG-TERM>                                    399,634
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,103
<OTHER-SE>                                   2,083,157
<TOTAL-LIABILITIES-AND-EQUITY>              15,485,216
<INTEREST-LOAN>                                706,460
<INTEREST-INVEST>                               87,365
<INTEREST-OTHER>                                14,761
<INTEREST-TOTAL>                               808,586
<INTEREST-DEPOSIT>                             356,044
<INTEREST-EXPENSE>                             405,872
<INTEREST-INCOME-NET>                          402,714
<LOAN-LOSSES>                                  (5,902)
<SECURITIES-GAINS>                               1,016
<EXPENSE-OTHER>                                407,948
<INCOME-PRETAX>                                272,194
<INCOME-PRE-EXTRAORDINARY>                     156,627
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   156,627
<EPS-BASIC>                                       1.64
<EPS-DILUTED>                                     1.61
<YIELD-ACTUAL>                                    4.31
<LOANS-NON>                                    234,783
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                             (113,000)
<CHARGE-OFFS>                                  (6,550)
<RECOVERIES>                                       648
<ALLOWANCE-CLOSE>                            (113,000)
<ALLOWANCE-DOMESTIC>                         (113,000)
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
George C. PUGH, Petitioner v. FLORIDA

No. 19-6360

Supreme Court of the United States.

November 25, 2019

Petition for writ of certiorari to the District Court of Appeal of Florida, First District denied.
Exhibit 10.1
 AMENDMENT NO. 3 TO THE SECURITIES PURCHASE AGREEMENT
     Non-competition Clause
 (a)
    
    Section 10.2 of the Agreement is hereby amended and restated to
read in full as follows:
 10.3 Non-Competition . In the event that the Second Closing
fails to occur, none of the VIASPACE Entities or their affiliates (except Acquirer,
including their officers Messrs. Kukkonen and Muzi to the extent each work for
Acquirer), or any of their directors or officers, shall engage in the Grass Business
for a period of three years after the First Closing Date.
 Acquirer Shares
 (a)
    
    Section 10.2 of the Agreement is hereby amended and restated to
read in full as follows:
 10.2 Shareholder Rights Upon Failure to Close . In the event that the
Second Closing fails to occur and Parents closing conditions to the Second Closing as
set forth in Sections 7.1 through 7.7, and 7.9 have been satisfied, then (1)
Shareholder and/or his designees shall retain the Acquirer Shares, (2) Parent shall
transfer all shares of Acquirer common stock it holds to Shareholder, (3) Shareholder
will deliver the remaining 30% equity interest of IPA BVI to Acquirer, such that
Acquirer shall receive all equity securities of IPA BVI, and (4) if Acquirers common
stock is not listed on a Trading Market as of the Second Closing Deadline, Shareholder
shall also receive such number of shares of Viaspace common stock so that Shareholder
shall own a majority of the outstanding shares of Viaspace common stock as of the date
of issuance.
 Notwithstanding any other provisions of this Agreement, Shareholder and/or his
designees shall retain the Acquirer Shares, irrespective of whether the Second Closing
occurs or does not occur or whether Parents closing conditions are satisfied or not.




---



##### 



Grass License
 Miscellaneous
 Effect of Amendment
 Counterparts
 Applicable Law
  2




---



##### 



VIASPACE INC.By:
    /s/ Carl KukkonenCarl KukkonenChief Executive OfficerVIASPACE GREEN ENERGY, INC.By:
    /s/ Carl KukkonenCarl KukkonenChief Executive OfficerSUNG HSIEN CHANG/s/ Sung Hsien ChangCHINA GATE TECHNOLOGY CO., LTD.By:
    /s/ Maclean WangMaclean WangChief Executive Officer  3
UNITED STATES AIR FORCE

COURT OF CRIMINAL APPEALS

________________________

No. ACM S32585 (f rev)

________________________

UNITED STATES

Appellee

v.

Joshua R. BROUSSARD

Senior Airman (E-4), U.S. Air Force, Appellant

________________________

Appeal from the United States Air Force Trial Judiciary

Upon Further Review

Decided 29 July 2020

________________________

Military Judge: Jennifer E. Powell.

Approved sentence: Bad-conduct discharge, confinement for 150 days, 

reduction to E-1, and a reprimand. Sentence adjudged 12 March 2019

by SpCM convened at Nellis Air Force Base, Nevada.

For Appellant: None. *

 

* On 12 March 2019, the same date as the announcement of sentence, Appellant executed an Air Force Form 304, Request for Appellate Defense Counsel (May 2000) (AF 

Form 304), electing to not request appellate defense counsel to represent him before 

this court. The AF Form 304 not only provides a means by which an appellant may 

request or decline appellate counsel, but also includes a declaration that the signatory 

understands that he or she is entitled to request appellate defense counsel, and that 

he or she is also entitled to retain civilian counsel at no expense to the Government. In 

United States v. Xu, 70 M.J. 140 (C.A.A.F. 2011) (mem.), the United States Court of 

Appeals for the Armed Forces concluded that an appellant’s waiver of counsel prior to 

the convening authority’s action was premature; therefore, an appellant is required to 

be provided another opportunity to elect if he or she requests appellate defense counsel 

after the convening authority takes action. This did not occur in Appellant’s case. On 

24 March 2020, this court remanded Appellant’s case to The Judge Advocate General 

for a determination as to whether Appellant desired appellate defense counsel repre-
United States v. Broussard, No. ACM S32585

2

Before MINK, LEWIS, and D. JOHNSON, Appellate Military Judges.

________________________

This is an unpublished opinion and, as such, does not serve as 

precedent under AFCCA Rule of Practice and Procedure 30.4.

________________________

PER CURIAM:

The approved findings and sentence are correct in law and fact, and no error materially prejudicial to Appellant’s substantial rights occurred. Articles 

59(a) and 66(c), Uniform Code of Military Justice, 10 U.S.C. §§ 859(a), 866(c). 

Manual for Courts-Martial, United States (2016 ed.). Accordingly, the approved findings and sentence are AFFIRMED.

FOR THE COURT

CAROL K. JOYCE

Clerk of the Court

 

sentation and ordered the record of trial returned to this court for completion of appellate review. On 27 March 2020, Appellant signed a second AF Form 304 indicating he 

did not want appellate defense counsel representation.
ROBERT W. MAUTHE, M.D., P.C., Petitioner v. OPTUM, INC., et al.

No. 19-413

Supreme Court of the United States.

November 25, 2019

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.
Rafael LEONER-AGUIRRE, Petitioner v. UNITED STATES

No. 19-6820

Supreme Court of the United States.

January 13, 2020

Petition for writ of certiorari to the United States Court of Appeals for the First Circuit denied.
# C_2022284EN.01002301.xml

| 25.7.2022 | EN | Official Journal of the European Union | C 284/23 |
| --- | --- | --- | --- |

25.7.2022

EN

Official Journal of the European Union

C 284/23

---

Judgment of the General Court of 18 May 2022 — Uzina Metalurgica Moldoveneasca v Commission

(Case T-245/19) (1)

(Safeguard measures - Market for steel products - Implementing Regulation (EU) 2019/159 - Action for annulment - Interest in bringing proceedings - Standing to bring proceedings - Admissibility - Equal treatment - Legitimate expectations - Principle of sound administration - Duty of care - Threat of serious injury - Manifest error of assessment - Initiation of a safeguard investigation - Competence of the Commission - Rights of the defence)

(2022/C 284/26)

Language of the case: English

Parties

Applicant: Uzina Metalurgica Moldoveneasca OAO (Rîbniţa, Moldova) (represented by: P. Vander Schueren and E. Gergondet, lawyers)

Defendant: European Commission (represented by: G. Luengo and P. Němečková, acting as Agents)

Re:

By its action under Article 263 TFEU, the applicant, Uzina Metalurgica Moldoveneasca OAO, seeks annulment of Commission Implementing Regulation (EU) 2019/159 of 31 January 2019 imposing definitive safeguard measures against imports of certain steel products (OJ 2019 L 31, p. 27), in so far as it applies to the applicant.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Uzina Metalurgica Moldoveneasca OAO is ordered to pay the costs. |
| --- | --- |

2.

Uzina Metalurgica Moldoveneasca OAO is ordered to pay the costs.

---

(1)  OJ C 230, 8.7.2019.

---
Monir GEORGE, Petitioner v. Dana METZGER, Warden

No. 19-6592

Supreme Court of the United States.

January 13, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.